Novel antipsychotics: hopes and limitations

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F00%3A00000037" target="_blank" >RIV/00023752:_____/00:00000037 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Novel antipsychotics: hopes and limitations
Original language description
The last decade has been an era of a thrilling development of new antipsychotic drugs. These novel antipsychotics, also called "atypical", have a different mechanism of action from the conventional neuroleptics. They are characterized by a lower affinityto dopaminergic D2 receptors and a relatively high affinity to the serotoninergic system. In addition to their potent efficacy on positive psychotic symptoms which is comparable to that of the antidopaminergic drugs, they can improve negative, and possibly also affective and cognitive symptoms. Novel antipsychotics are associated with a low incidence of extrapyramidal side effects and tardive dyskinesia; this fact can assure better compliance. A prototype of this class is clozapine, a drug with well documented side effects and efficacy in treatment-resistant patients. Despite the growing number of publications and data on other novel drugs (risperidone, olanzapine, quetiapine), there is a lack of knowledge on effects in more specific p
Czech name
—
Czech description
—

Publication year
2000
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Book/collection name
5th Congress of the European Society for Clinical Neuropsychopharmacology, Opatija (Croatie), May 17 - 21, 2000
ISBN
—
Number of pages of the result
6
Pages from-to
—
Number of pages of the book
—
Publisher name
Monduzzi Editore
Place of publication
Bologna
UT code for WoS chapter
—

Similar results(10)